Jennifer Hughes, APRN
Family · Leitchfield, KYNPI 1700307451
Payments from drug & device makers
Across 96 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$426
- Organogenesis Inc.$357
- Karyopharm Therapeutics Inc.$96
- Takeda Pharmaceuticals U.S.A., Inc.$93
- Smith+Nephew$86
- Lilly USA, LLC$68
- plus $569 from 19 others
What the payments were for
- Food & beverage$1,696100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $426 |
| Organogenesis Inc. | 18 | $357 |
| Karyopharm Therapeutics Inc. | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| Smith+Nephew | 4 | $86 |
| Lilly USA, LLC | 4 | $68 |
| Integra Lifesciences Corporation | 3 | $66 |
| Kerecis Limited | 2 | $65 |
| Reapplix Inc. | 2 | $56 |
| Reprise Biomedical, Inc. | 3 | $47 |
| AVEO Pharmaceuticals, Inc. | 3 | $39 |
| Convatec Inc. | 2 | $38 |
| Johnson & Johnson | 1 | $34 |
| Novo Nordisk | 2 | $30 |
| Pfizer | 2 | $27 |
| Merck | 2 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Solventum Corporation | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Amgen | 1 | $15 |
| KCI USA, Inc. | 1 | $15 |
| Polymedics Innovations Inc. | 1 | $13 |
| GSK | 1 | $11 |
How this compares
$1,696 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 16 | $39,355 |
| Clobetasol Propionate | 26 | $685 |
| Doxycycline Hyclate | 75 | $568 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $116 |
| Cephalexin | 24 | $107 |
| Mupirocin | 13 | $99 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $42 |
| Ciprofloxacin Hcl | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Other family in Leitchfield
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.